Cargando…
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo
BACKGROUND: Former studies already revealed the anti-neoplastic properties of the anti-infective agent Taurolidine (TRD) against many tumor species in vitro and in vivo. Its anti-proliferative and cell death inducing capacity is largely due to its main derivative Taurultam (TRLT). In this study it c...
Autores principales: | Buchholz, M., Majchrzak-Stiller, B., Hahn, S., Vangala, D., Pfirrmann, R. W., Uhl, W., Braumann, C., Chromik, A. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366103/ https://www.ncbi.nlm.nih.gov/pubmed/28340556 http://dx.doi.org/10.1186/s12885-017-3204-x |
Ejemplares similares
-
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study
por: Baron, Claudia, et al.
Publicado: (2022) -
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo
por: Buchholz, Marie, et al.
Publicado: (2022) -
GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells
por: Majchrzak‐Stiller, Britta, et al.
Publicado: (2023) -
The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results
por: Gambichler, Thilo, et al.
Publicado: (2023) -
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes
por: Gambichler, Thilo, et al.
Publicado: (2023)